Abstract Number: 3025 • 2015 ACR/ARHP Annual Meeting
FcγRIIIa-Psyk Signaling up-Regulates TLR3 and TLR5 in Human Naïve CD4+ T-Cells
Background/Purpose: To delineate mechanism of FcγRIIIa-pSyk signal in TH17 and IFN-γhigh subset development. To examine whether Toll-like receptor signaling play a role in CD4+ T-cell…Abstract Number: 740 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus
Background/Purpose: Autoantibodies to the nuclear autoantigen dense fine speckles 70 (DFS70) are associated with a new paradigm whereby when they are found in isolation (monospecific…Abstract Number: 1067 • 2015 ACR/ARHP Annual Meeting
Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis
Background/Purpose: Prior studies suggest that males with lupus nephritis (LN) may have worse outcomes than females. However, the majority of these studies, are from tertiary-care…Abstract Number: 1784 • 2015 ACR/ARHP Annual Meeting
Treatment with Belimumab in SLE Does Not Impair Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine
Background/Purpose: To explore the impact of SLE disease and belimumab given in addition to standard of care therapy on antibody response after vaccination with PCV13…Abstract Number: 2045 • 2015 ACR/ARHP Annual Meeting
Cross-Validation of the Pediatric Automated Neuropsychological Assessment Metrics-Cognitive Performance Scores in the Screening of Neurocognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Neurocognitive impairment (NCI) is an important morbidity in childhood-onset systemic lupus erythematosus (cSLE); however, the gold standard formal neuropsychological assessment is difficult to access. Screening for…Abstract Number: 3030 • 2015 ACR/ARHP Annual Meeting
Increased Localization of Spleen Tyrosine Kinase (Syk) in Lipid Rafts of in Vitro TCR/CD3-CD28 Activated Lupus T Cells
Background/Purpose: Numerous alterations in signal transduction in SLE T cells have been previously reported. Diminished expression of the ζ chain of the TCR/CD3 complex has been…Abstract Number: 13 • 2015 ACR/ARHP Annual Meeting
Altered Soluble Mediators, Autoantibodies, and Lupus-Specific Connective Tissue Disease Questionnaire Scores Distinguish Blood Relatives with Incomplete Lupus from Unaffected Relatives and Relatives with Classified SLE
Background/Purpose: Blood relatives (Rel) of lupus patients have increased risk of SLE. Some have autoantibodies and SLE clinical features, but do not meet ≥ 4…Abstract Number: 749 • 2015 ACR/ARHP Annual Meeting
Microvesicles Containing Nucleic Acids and Expressing Immunoglobulins and HMGB1 Are Abundant in Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by immune complexes of antinuclear antibodies. As a source of these antigens, increased levels…Abstract Number: 1069 • 2015 ACR/ARHP Annual Meeting
Child’s HLA-DRB1 Genotype Increases Maternal Risk of Systemic Lupus Erythematosus: Results from the Mother-Child Immunogenetic Study in Autoimmunity
Background/Purpose: SLE [MIM 152700] disproportionately affects women of reproductive age and pregnant patients are more likely to experience flares. Fetal microchimerism (FMC), or the persistence…Abstract Number: 1789 • 2015 ACR/ARHP Annual Meeting
Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Background/Purpose: SLE is associated with a significantly increased risk of infection. Both disease activity and the medications required to control disease are contributory factors. Rituximab…Abstract Number: 2067 • 2015 ACR/ARHP Annual Meeting
De-Convolution of Whole Blood Transcriptomic Data from a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept in Systemic Lupus Erythematosus
Background/Purpose: The Phase IIb IM101-042 trial was a randomized, double-blind, placebo-controlled trial of abatacept (ABA) in systemic lupus erythematosus patients (pts) with polyarthritis, discoid lesions…Abstract Number: 3081 • 2015 ACR/ARHP Annual Meeting
IRF5 Deletion Prevents the SLE-like Disease Initiated By Dendritic Cell-Specific Loss of Caspase 8
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE). While DCs from SLE patients exhibit elevated activation,…Abstract Number: 56 • 2015 ACR/ARHP Annual Meeting
Utilizing City-Wide Electronic Health Record Data to Assess Care Fragmentation in Patients with Systemic Lupus Erythematosus (SLE)
Background/Purpose: Care fragmentation is associated with poor health outcomes and is hard to assess in a single-site data registry. The Chicago HealthLNK Data Repository (CHDR)…Abstract Number: 753 • 2015 ACR/ARHP Annual Meeting
Serum Levels of Tenascin-C Discriminate Patients with Active SLE from Inactive Patients and Healthy Controls, and Predict the Need to Escalate Immunosuppressive Therapy
Background/Purpose: The aim of this study was to examine whether circulating levels of the pro-inflammatory glycoprotein tenascin-C (TSC) are useful as an activity-specific or predictive…Abstract Number: 1070 • 2015 ACR/ARHP Annual Meeting
CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE
Background/Purpose: Cluster of differentiation 14 (CD14) plays an important role in innate immune system as a co-receptor in TLRs (2, 4, 7 and 9) signaling.…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 38
- Next Page »